Ayurveda for Respiratory Disorders — Pranavaha Srota — Ayurvedic Benefits, Uses & Precautions | MyMedicPlus

Respiratory disorders in Ayurveda are organized under two major disease categories: Kasa (cough), which includes five subtypes differentiated by dosha dominance — Vataja, Pittaja, Kaphaja, Kshataja (traumatic), and Kshayaja (consumptive) — and Shwasa (dyspnea/breathlessness), also with five subtypes ranked by clinical severity from Mahashwasa (terminal) to Tamaka Shwasa (bronchial asthma). Both categories are governed by the health of Pranavaha Srota, the subtle channels carrying Prana Vayu (vital breath) through the lungs and bronchial tree to all tissues. Charaka Samhita specifically names Tamaka Shwasa as the Ayurvedic clinical equivalent of bronchial asthma, characterized by nocturnal worsening, audible wheezing, upright-position relief, and triggered by cold, smoke, and dust — a remarkably accurate clinical description. Both Kasa and Shwasa are listed among the eight Mahagada (serious disease groups) due to the complexity of management and their life-limiting potential when untreated. Treatment strategy begins with identifying the dominant doshic combination — Kapha obstruction in airways versus Vata derangement in respiratory muscles — determining whether Shodhana (purification) or Shamana (palliative) is the correct primary approach.

Vamana (therapeutic emesis) is the principal Panchakarma procedure for Kapha-dominant respiratory conditions, particularly chronic bronchial asthma and recurrent bronchitis. Because the stomach is Kapha's primary anatomical seat, Vamana eliminates accumulated Kapha at its source and interrupts the cycle of Kapha re-ascending into the lungs and airways. Nasya with Shad Bindu taila clears Kapha obstruction from the nasal passages, sinuses, and upper respiratory channels, while also acting on the nervous system pathways serving the lungs. Key classical oral formulations include Sitopaladi Churna for all types of Kasa, Kanakasava for Shwasa with pronounced bronchospasm, Talisadi Churna for productive cough accompanied by fever, and Agastya Haritaki Rasayana for chronic respiratory debility requiring tissue rebuilding. Dhoomapana — therapeutic smoke inhalation using dried Vasa (Adhatoda vasica) leaves or Haritaki — provides rapid bronchodilator relief during acute bronchospasm episodes. Pranayama (structured breathing practices) is mandated in Ashtanga Hridayam as an ongoing preventive and rehabilitative practice alongside all oral and procedural treatments for respiratory conditions.

Vasaka (Adhatoda vasica) contains the quinazoline alkaloids vasicine and vasicinone, which produce bronchodilator and mucolytic effects through mechanisms pharmacologically comparable to bromhexine — confirmed in multiple in vitro and human clinical studies. Vasicine also acts as a uterotonic, explaining its strict contraindication in pregnancy. Kantakari (Solanum xanthocarpum) alkaloid solasodine reduces bronchial hyperreactivity and inhibits mast cell degranulation, thereby reducing allergic airway inflammation at a cellular level. Tulsi (Ocimum sanctum) contains eugenol which inhibits arachidonic acid metabolism via COX-2 suppression, reducing histamine-mediated bronchospasm with anti-inflammatory potency comparable to indomethacin in animal pharmacology studies. Pippali (Piper longum) piperine enhances bioavailability of co-administered herbs by 20 to 40% through P-glycoprotein inhibition and CYP3A4 modulation, while also directly stimulating respiratory mucociliary clearance. Yashtimadhu (Glycyrrhiza glabra) glycyrrhizin suppresses airway inflammation, reduces bronchial hyperreactivity, and promotes mucus secretion from bronchial glands as an expectorant. These herbs work synergistically in classical compound formulations, with each targeting a distinct mechanistic pathway in the respiratory disease process.

Vasaka (Adhatoda vasica) extract significantly reduces bronchospasm frequency, sputum viscosity, and airway resistance in patients with asthma and COPD across published clinical trials, with measurable improvement within two weeks of consistent use. Sitopaladi Churna reduces cough frequency, severity, and sputum production in acute respiratory infections within five to seven days, consistently outperforming placebo in Ayurvedic clinical studies. Daily Tulsi supplementation at 300mg twice daily reduces the frequency and duration of upper respiratory infections by enhancing innate immune responses, including natural killer cell activity and interferon-gamma production. Ayurvedic Vamana therapy, properly administered with complete Purvakarma preparation, achieves durable asthma symptom control in Kapha-dominant patients, with clinical studies reporting effects maintained for up to six months post-treatment — comparable to low-dose inhaled corticosteroids in select populations. Pranayama practice over eight to twelve weeks improves peak expiratory flow rate and FEV1 significantly in mild-to-moderate asthma patients, with benefits persisting beyond the intervention period. Kanakasava reduces frequency of Shwasa episodes in chronic asthma when used as long-term maintenance therapy alongside lifestyle modification.

Sitopaladi Churna is administered at 3 to 5 grams with honey three times daily before meals for all types of cough, including productive (Kaphaja, Pittaja) and dry (Vataja) varieties, making it the most versatile classical respiratory formula. Vasaka fresh leaf juice at 20ml, or Vasa Avaleha (electuary form), is prescribed specifically for productive cough with bronchospasm in acute bronchitis and asthmatic episodes, taken twice daily on an empty stomach. Steam inhalation with Eucalyptus oil, fresh Tulsi leaves, and grated ginger in hot water provides adjunct bronchodilator and mucolytic benefit and may be repeated two to three times daily throughout the acute phase. Vamana therapy, conducted by qualified Ayurvedic physicians in a supervised clinical setting after thorough Snehana and Swedana preparation over seven days, provides the most sustained long-term benefit for chronic Kapha-dominant asthma. Kanakasava at 15ml twice daily after meals is the standard liquid formulation for chronic Shwasa and should be continued for at least three months to assess full benefit. Pranayama — specifically Bhastrika for Kapha clearance, Anuloma Viloma for bronchial balance, and Bhramari for nervous system calming — practiced for 20 to 30 minutes daily is mandatory as a non-negotiable adjunct for respiratory rehabilitation.

Clinical evidence for Ayurvedic respiratory therapies is strongest for individual herbs and pranayama. A study by Dhuley (1999) published in the Journal of Ethnopharmacology confirmed that Adhatoda vasica leaf extracts produce significant bronchodilation and reduce airway hypersecretion in animal models, validating the classical bronchodilator action attributed to vasicine. A randomized controlled trial by Manocha et al. (2002, Thorax) demonstrated that yoga and pranayama significantly improved quality-of-life scores and asthma symptom frequency compared to conventional management alone, with sustained effects at follow-up. Tulsi's anti-inflammatory properties are supported by in vitro studies confirming COX-2 inhibition, and small clinical trials show reduced frequency of upper respiratory infections with supplementation. Piperine from Pippali has been confirmed to enhance bioavailability of multiple drugs in human pharmacokinetic studies, lending scientific support to the traditional practice of using Trikatu as a bioavailability enhancer. Evidence for complete Ayurvedic protocols including Vamana and multi-herb formulations remains preliminary, with most studies lacking adequate blinding, standardized outcome measures, or sufficient sample sizes. Patients with diagnosed asthma or COPD should regard Ayurvedic therapy as complementary to, not a replacement for, prescribed inhalers and medical management.

Vasaka (Adhatoda vasica) is a potent uterotonic and emmenagogue and is strictly contraindicated throughout pregnancy and in women who are trying to conceive, as it can stimulate uterine contractions and cause miscarriage. Vamana therapy must never be performed during active asthma attacks or acute exacerbations of COPD, in elderly or profoundly debilitated individuals, in those with significant cardiovascular disease, or in anyone who has not undergone proper Purvakarma preparation. The most serious safety risk in Ayurvedic respiratory care is the premature discontinuation of life-saving conventional medications: prescribed rescue inhalers such as salbutamol, inhaled corticosteroids, leukotriene modifiers, and systemic steroids must never be reduced or stopped without explicit approval from the treating pulmonologist. Acute respiratory distress — indicated by oxygen saturation below 94%, respiratory rate above 30 breaths per minute, cyanosis, accessory muscle use, or inability to complete full sentences — requires immediate emergency medical care and is entirely inappropriate for Ayurvedic management alone. Dhoomapana (medicated smoke inhalation) is contraindicated during active asthma attacks and in individuals with sensitized airways who may experience paradoxical bronchospasm. Pippali and Trikatu in high doses over extended periods may cause gastric mucosal irritation and should be used with caution in peptic ulcer disease. All Panchakarma procedures for respiratory disorders must be assessed and supervised by a qualified BAMS-credentialed Ayurvedic physician.